Journal ArticleOPEN ACCESS

Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States

Blood (2024) 143(22) 2332-2335
DOI: 10.1182/blood.2024024209
4Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We evaluated the cost-effectiveness of prophylaxis with recombinant von Willebrand factor (rVWF) vs with plasma-derived von Willebrand factor (pdVWF) for patients with severe Von Willebrand disease. We found that rVWF is a cost-saving factor replacement compared with pdVWF across all willingness-to-pay thresholds in the United States.

Cite

CITATION STYLE

APA

Waldron, C., Ito, S., Wang, D., Allen, C., Viswanathan, G., Bona, R. D., … Goshua, G. (2024). Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States. Blood, 143(22), 2332–2335. https://doi.org/10.1182/blood.2024024209

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free